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Overexpression of drug efflux pumps at the blood brain barrier (BBB) has been suggested to be one important
factor contributing to drug resistance in epilepsy. This would imply that resected brain tissue of drug-resistant
patients is drug-sensitive in absence of the BBB. Here we studied the effects of carbamazepine (CBZ)
at therapeutically relevant concentration on epileptiform activity electrophysiologically recorded in acute
hippocampal slices of patients with mesial temporal lobe epilepsy (MTLE; 28 patients, 49 slices) or extra-
hippocampal tumours (tumour; 6 patients, 11 slices). Epileptiform activity was induced by hilar stimulation
(0.067 Hz) during elevation of extracellular potassium concentration ([K+]o) and remained self-sustained in
presence of 10–12 mM [K+]o. Quantitative analysis of data revealed that epileptiform activity in tissue of
tumour-patients was predominantly suppressed by CBZ, indicating that the ‘epilepsy model’ used is CBZ-
sensitive. In contrast, epileptiform activity in tissue of drug-resistantMTLE patients was resistant to CBZ in 82%
of patients, partially suppressed in 11% and completely suppressed in 7%. The effects of CBZ in tissue of MTLE
patients did not depend on the type of activity, hippocampal pathology, excitability of the tissue, or equilibration
time of the drug. Considering that CBZ has direct access to all compartments of the slice, our results suggest
that CBZ-resistance mechanisms are located within the parenchyma of the dentate gyrus and contribute to
drug resistance in the majority of MTLE patients. BBB-located drug-resistance mechanisms per se may play a
minor role in this region, because CBZ-sensitivity was only observed in 7% of CBZ-resistant patients.
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SLE = seizure- like event
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Introduction
Drug resistance is a crucial problem in the treatment
of focal epilepsies. Many patients suffering from mesial
temporal lobe epilepsy (MTLE) do not attain seizure control
despite appropriate medical treatment, particularly in MTLE
associated with hippocampal sclerosis (HS) (Semah et al.,
1998). A selected group of MTLE-patients benefit from
surgical resection of the epileptogenic tissue (Engel, 1996),
suggesting that the removed tissue is characterized by
hyperexcitability and drug resistance. Slices of both sclerotic
and non-sclerotic hippocampal tissue can be successfully
challenged to develop ongoing spontaneous epileptiform
activity in the dentate gyrus (Gabriel et al., 2004). This
provides an intriguing possibility to study effects of anti-
epileptic drugs (AEDs) in human epileptic tissue of drug
resistant patients (Remy et al., 2003a).
The nature of drug resistance is likely multifactorial. The
most favoured concept suggests that ATP-dependent drug
efflux pumps (Lee et al., 2001; Lo¨scher and Potschka, 2005a),
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which are up-regulated in epilepsy (Tishler et al., 1995;
Lazarowski et al., 1999; Dombrowski et al., 2001; Marchi
et al., 2005), impede the penetration of drugs into the
epileptogenic tissue, thus keeping the concentration of drugs
low at the cellular targets (transporter hypothesis) (Abbott
and Romero, 1996; Abbott et al., 2002; Kwan and Brodie,
2005; Lo¨scher and Potschka, 2005b, c). Drug efflux pumps
are overexpressed at the blood brain barrier (BBB) (Aronica
et al., 2003a, b, 2004; Calatozzolo et al., 2005) or in astrocytes
around the microvasculature (Golden and Pardridge, 2000;
Sisodiya et al., 2001, 2002). This would imply that direct
application of the AED into the epileptic tissue overrides
drug resistance at the BBB and block epileptiform activity.
Alternatively, drug resistance may result from functionally
or genetically modified sensitivity of drug targets (target
hypothesis) (Remy and Beck, 2006). This concept suggests
that epileptic tissue does not respond to AEDs at thera-
peutically relevant concentration in the brain parenchyma.
Additionally, drug transporters ectopically expressed in neu-
rons and astrocytes of sclerotic hippocampal tissue
(Aronica et al., 2004) pump the drugs out of the intra-
cellular compartment. This may contribute to failure of
the cellular drug response, provided the drug binds to
an intracellular target site.
The present study has been undertaken to find out
whether epileptiform activity in the dentate gyrus of epilepsy
patients would be sensitive to AEDs which have direct
access to the parenchyma. For this purpose we investigated
acute hippocampal slices from resected tissue of patients
operated on MTLE or extra-hippocampal tumours. We
chose carbamazepine (CBZ) because it is a frequently used
but non-effective AED in patients considered for epilepsy
surgery (Hermanns et al., 1996; Wieser and Ha¨ne, 2003).
CBZ is thought to be a substrate of drug transporters
(Lo¨scher and Potschka, 2002) and exerts its anticonvulsant
action by blocking voltage-gated sodium channels in a use-
and frequency-dependent manner (Willow et al., 1985;
Schwarz and Grigat, 1989; Kuo, 1998; Ragsdale and Avoli,
1998; Remy and Beck, 2006).
Here we describe that epileptiform activity in acute
brain slices of epilepsy patients is CBZ-resistant in the
majority of MTLE-patients. Effects of CBZ depend rather on
the cause and duration of epilepsy than on the type of
activity or hippocampal pathology.
Material and methods
Clinical diagnosis
Human hippocampi were surgically resected in order to cure medi-
cally intractable temporal lobe epilepsy (n = 28) or to remove
tumours nearby (n = 6). Drug resistance has been assumed when
seizure control could not be obtained by two or three AEDs increa-
sed to maximal tolerated dose within 2 years (Dlugos, 2001). The
pre-surgical evaluation of MTLE was performed in the Epilepsy-
Center of Berlin-Brandenburg according to the German and
European guidelines for pre-surgical evaluation (Baumgartner et al.,
2000; European Federation of Neurological Societies Task Force,
2000). Some of the tumour cases were diagnosed and prepared for
surgical intervention in the Department of Neurosurgery. The
study was approved by the Ethics Committee at the Charite´
(EA125/2001, EA1/042/04) and performed in accordance with the
Declaration of Helsinki. A written informed consent for the study
was obtained from every patient before surgery. All operations were
done by one of the authors (T.-N.L.) guaranteeing the same
dissection technique of the hippocampus.
Neuropathological diagnosis
Neighbouring sections of the tissue investigated for effects of CBZ
were analysed by the Department of Neuropathology at the Charite´
for diagnostic purposes. As already described in detail (Gabriel
et al., 2004; Kann et al., 2005), removed hippocampi were divided
into two groups according to the degree of nerve cell loss, using the
Wyler classification (Wyler et al., 1992). In short, Wyler grades
1 and 2 were grouped to ‘nonHS’ (HS for hippocampal sclerosis),
while grades 3 and 4 were grouped to ‘HS’. As the degree of
sclerosis varies throughout the hippocampus (Masukawa et al.,
1995), we always repeated the Wyler grading on cresyl violet stained
sections from the tissue investigated in our laboratory. If different
grading results were obtained (n = 2), we used the grading of the
tissue studied for the effects of CBZ.
Tissue transport, preparation and
maintenance
Two to three coronal sections of 4 mm thickness were cut from
the hippocampal head and body in the operation theatre and
immediately incubated in cold (1–4C) carbogenated transport
solution containing (in mM) KCl 3, NaH2PO4 1.25, glucose 10,
MgSO4 2, MgCl2 2, CaCl2 1.6, NaHCO3 21, sucrose 200 and (6)
a-tocopherol 0.1 (pH 7.4, osmolality 303 mosmol/ kg, 0.005 v%
ethanol) (Gabriel et al., 2004; Kann et al., 2005). Transport to
the laboratory was performed in an airtight cooling receiver
within 30 min. At arrival in the laboratory the temperature of
the solution was still <4C and partial pressure of oxygen was
>580 torr.
Subsequently, the tissue was coronally dissected into slices of
500 mm thickness using a vibratome (Campden Instruments Ltd,
Leicester, UK). The slices were immediately transferred into
interface chambers, perfused at a rate of 1.7 ml/min with pre-
warmed (34.5 6 0.5C) carbogenated artificial cerebrospinal fluid
(ACSF) containing (in mM): NaCl 129, KCl 3, NaH2PO4 1.25,
glucose 10, MgCl2 2, CaCl2 1.6, NaHCO3 21 (pH 7.4, osmolality
300 mosmol/kg). Recordings commenced 4 h after preparation of
slices to permit optimal recovery after surgery and transport in
sodium free solution.
Electrophysiological recordings and
stimulation
Extracellular recordings as well as hilar stimulation were performed
as previously described (Gabriel et al., 1998). The recording
electrode was placed into the dentate granule cell layer, opposite to
area CA1. We used double-barreled K+-selective/reference micro-
electrodes (containing Fluka 60031 ionophore backfilled with
100 mM KCl/150 mM NaCl, respectively) which were prepared and
tested as described by Lux and Neher (1973). All electrodes
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responded to a 10-fold change in K+-concentration with a potential
shift of 60 mV. Field potential and extracellular potassium con-
centration ([K+]o) were continuously recorded using Spike2
(version 4.01, CED; Cambridge, UK) with sample rates of 5 kHz
for field potentials (filter cut-off 1 kHz) and 100 Hz for [K+]o (filter
cut-off 1.6 Hz).
Bipolar stimulation electrodes (platinum wires of 20 mm
diameter, tip separation 40–80 mm) were positioned at the hilus/
CA3 border. In order to confirm slice viability and to assess similar
stimulation efficacy with respect to the level of neuronal activation
in all slices, paired stimuli (0.1 ms, 1–30 V, 50 ms interval) with
intensities eliciting similar proportions of the maximal population
spike amplitude in different slices were applied every 20 s, in the
beginning and at the end of each experiment. Slices displaying
maximal population spike amplitudes of <1.5 mV in the beginning
or loss of >20% of the maximal amplitude at the end of the
experiment were excluded from the analysis.
Experimental protocol
Epileptiform activity was induced by continuous paired hilar
stimulation (0.067 Hz, intensity eliciting population responses with
80% of the maximum amplitude) and perfusion with ACSF con-
taining 10–12 mM [K+] (high K-ACSF). When epileptiform events
occurred independently of stimulation, the stimulation was turned
off. Then, each experiment was divided in three subsequent periods:
First, we waited for another 5–15 min until the epileptiform
activity had stabilized with respect to event rate and amplitude
(control).
Second, we changed the perfusion medium to CBZ-high
K-ACSF, with CBZ (RBI/Sigma, Deisenhofen, Germany; pre-
dissolved at 100 mM in dimethylsulfoxide) at a final concentration
of 50 mM for at least 20 min (CBZ).
Third, we changed the perfusion medium back to high K-ACSF
in order to wash out CBZ for 20–60 min (wash).
In some experiments, the drug perfusion was prolonged for
another 20 min, applying CBZ at concentrations of either 50 or
100 mM. A concentration of 50 mM CBZ corresponds to upper
therapeutically relevant serum levels (Strandjord and Johannessen,
1980; Semah et al., 1994; Neels et al., 2004), while 100 mM CBZ is
in the supra-therapeutic range.
Procedures of data analysis
Categorization of epileptiform activity
As recently reported, four types of epileptiform events occurred
in the dentate gyrus (Gabriel et al., 2004). They were categorized
as (i) tonic–clonic seizure-like events (tonic–clonic SLEs) when
slow negative field potential shifts of >5 s duration were super-
imposed by a high frequency fluctuation of small transients and
subsequent low frequency clonic-like discharges; (ii) ictal spiking
when very short negative discharges with event rates >40/min)
continuously occurred; (iii) inter-ictal spiking when negative field
potential transients corresponding to inter-ictal spikes or spike-wave
complexes with event rates <40/min appeared; and (iv) tonic SLEs
when low frequency negative field potential shifts of >5 s duration
without superimposed clonic-like discharges were recorded.
Quantification of drug effects on epileptiform activity
The aim of this analysis was to quantify the changes of epileptiform
activity following perfusion with CBZ-high K-ACSF (Fig. 1). At
least 3, and up to maximum of 15 epileptiform events from the last
3 min epoch of each experimental period (control, CBZ, wash)
were analysed.
In order to characterize different frequency components and
amplitudes we determined six activity parameters: event rate
(ev/min); slow field potential amplitude [sfp (mV), considering the
smooth field potential shift]; peak amplitude [peak (mV), including
the largest transients, superimposed on the sfp]; and event duration
[duration (s), measured from start up to two-thirds recovery of
the sfp]. Amplitudes and duration are illustrated in Fig. 1A, A1.
The fifth parameter represents the mean frequency of transient
potential fluctuations (with minimal size of 0.3 mV and a minimal
time interval of 3 ms) superimposed on the sfp [frequency (Hz),
see Fig. 1A, A2]. The last parameter, power of the high frequency
band [Pb 78–293 Hz (mV
2), Fig. 1A, A3], estimates the high frequency
component of epileptiform events. Its determination included:
band pass filtering of field potential traces (80–300 Hz; Fig. 1A,
A3A), computation of the power spectrum from the resulting
high frequency event (Fig. 1A, A3B), and calculation of the sum
of power from single frequency intervals (19.53 Hz) between 78
and 293 Hz. This analysis was performed using the available tools
of the Spike2 program and additional homemade script files
(Dr H. Siegmund, Institute of Neurophysiology, Charite´).
Subsequently, the values taken from each event were separately
averaged for each parameter and analysis epoch. In order to
quantify the effects of CBZ the parameter values of the CBZ-epoch
were normalized with respect to a reference value. At the time
points of analysis, the high K-ACSF had been perfused for 20–40,
40–60 and 100–120 min. Irrespective of the presence of CBZ,
all types of epileptiform activity displayed an ongoing change of
parameter values during the course of recurrent spontaneous
activity (Fig. 1B). Therefore, we calculated the reference value
(100% ‘without CBZ’) as the mean value of control (e.g. 20 min in
Fig. 1B) and wash epochs (e.g.100 min in Fig. 1B).
Effects of CBZ were normalized and expressed as percent
of the reference value maintained after perfusion of CBZ [(CBZ
value/reference value) · 100]. In order to quantify the propor-
tion of slices showing gradual different effects of CBZ, we averaged
all normalized CBZ-parameters for each slice and graded the
remaining averaged percentages of activity between 0 and 20%,
21 and 70% and >70% as suppressed, reduced and resistant,
respectively. This categorization was derived from the bimodal
histogram of the values with peaks at 0–10 and 90–100%, calculated
for the whole sample of 60 slices as shown in Fig. 8B.
Statistics
Patients and slices were grouped according to clinical data,
neuropathological diagnosis, and types of epileptiform activity
observed during the experiments. Group data of ratio variables are
displayed as mean 6 SEM, throughout the paper. Data of nominal
and ordinal variables are given as proportions of group members
assigned to the categories. Statistical comparisons within and
between groups were performed using the Wilcoxon matched-pair
signed rank test (referred to as Wilcoxon test) and the Mann–
Whitney U-test or parametric procedures like the dependent
sample t-test and one-way analysis of variance including post hoc
tests, respectively. Proportional differences between groups were
evaluated applying the x2 homogeneity test. Relations between
two parameters were indicated as Pearson correlation coefficient
or Spearman rank correlation coefficient. All statistics were
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calculated using the SPSS software package Version 12.0.1 (SPSS,
Chicago, IL).
Results
Data of experiments on 60 slices from 34 hippocampal
specimens were analysed. The sample consisted of 49 slices
of 28 patients with drug-resistant MTLE (MTLE-group) and
11 slices from 6 patients diagnosed to suffer from tumours
(tumour group). All slices were studied between 6 and 24 h
after surgical resection and responded to electrical stimula-
tion at the hilus/CA3 border with one or more population
spikes in the granule cell layer. Maximal population spike
amplitudes were in the range of 1.5–10 mV in the beginning
of the experiment and in the range of 1.3–9.2 mV at the
end of the experiment. Here we describe the effects of
bath-applied CBZ on epileptiform activity induced in
hippocampal slices. Notably, drugs that are bath-applied
directly enter the parenchyma and do not have to cross
the BBB. The equilibration time necessary to reach the
maximal target concentration of the lipophilic drug is not
known, but our experiments with longer application time
show that there is no large change of the drug effect with
Fig. 1 Analysis of epileptiform activity. The activity has been induced by paired hilar stimulation (0.067 Hz, intensity eliciting 80%
of the maximal population spike amplitude) and elevation of [K+]o (10–12 mM). (A) Extraction of event parameters from an SLE.
(A1) Determination of event amplitudes and event duration: sfp = maximal amplitude of the slow field potential shift;
peak = peak amplitude (including maximal negative transients); duration = time from start of the slow field potential shift up to
two-thirds of recovery. (A2) Determination of intra-event frequency by counting transients >0.3 mV per time of the discharge period
(minimal time interval 3 ms). (A3) Determination of the power of the high frequency band (78–293 Hz) including (A3A) band pass
filtering of trace A1 (80–300 Hz), (A3B) calculation of the power spectrum from trace A3A (fi = 19.53 Hz) and summation of
power from frequency intervals between 78 and 293 Hz. (B) Time course of epileptiform activity (without drug application) showing
progressive changes of amplitude and event rate on an example of ictal spiking. Based on these changes we determined the
reference value as average of control value (e.g. derived from the 20 min trace) and the recovery value (e.g. taken from the
100 min trace).
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prolonged equilibration time (40 min). We saw the first
blocking effects already after 10 min in both sclerotic and
non-sclerotic tissue. Therefore, we assume that effective
concentration of CBZ might be already attained after
20 min.
Epileptiform activity in slices of the
MTLE-group is resistant to CBZ
irrespective of the type of activity
In the MTLE-group, we induced epileptiform activity in
the dentate gyrus of 34 slices from 19 sclerotic specimens
(Fig. 2A, HS, top) and in 12 slices of 9 non-sclerotic
specimens (Fig. 2A, nonHS, bottom). Four types of epilep-
tiform activity/epileptiform events were observed (Fig. 2B):
(i) tonic–clonic SLEs (first trace), (ii) ictal spiking (second
trace), (iii) inter-ictal spiking (third trace) and (iv) tonic
SLEs (fourth trace). Details of their characteristic activity
parameters (reference values) are given in Table 1. Tonic–
clonic SLEs exclusively appeared in sclerotic specimens
while tonic SLEs only occurred in the non-sclerotic tissue
(P < 0.001, x2-test). The data so far were consistent with
those recently reported by our group (Gabriel et al., 2004).
In the tumour-group, non-sclerotic slices developed tonic
SLEs (90%) and inter-ictal spiking (10%) whereas ictal
spiking was observed in one slice from a sclerotic specimen
of a CBZ-sensitive patient.
As different types of epileptiform activity may be more
or less sensitive to AEDs (Dreier and Heinemann, 1991),
we first compared effects of CBZ between the four types of
epileptiform activity in the MTLE-group. The results are
displayed in the summary graph of Fig. 2C. After 20 min
perfusion with 50 mM CBZ-containing high K-ACSF the
mean activity parameters of all event types remained in a
range of 76–108% of the reference value, clearly indicating
resistance to CBZ. One-way-analysis of variance including
post hoc tests (Bonferroni or Dunnett-T3 depending on
homogeneity of variances) did not yield differences of the
remaining activity between different events, suggesting
similar effects of CBZ on the four types of epileptiform
activity. Therefore, we were able to pool normalized data
from different epileptiform activities in order to compare
CBZ-effects between slices of different patient groups. We
subdivided the MTLE-group according to hippocampal
pathology and compared CBZ-effects between three slice
groups: HS-MTLE, nonHS-MTLE and tumour (all nonHS
except one sclerotic slice obtained from a CBZ-sensitive
patient).
Epileptiform activity is resistant to CBZ in
slices of the MTLE-group, irrespective of
the hippocampal pathology
The groups consisted of 34 slices (19 patients with
HS-MTLE), 15 slices (9 patients with nonHS-MTLE), and
11 slices (6 patients (5 nonHS-tumour, 1 HS-tumour)). In
Figs 3A–C and 4 sample traces are shown for each group.
In spite of CBZ application, the epileptiform activity
persisted as long as high K-ACSF has been perfused, in
both the HS-slice and the nonHS-slice from the MTLE
group. The HS-MTLE slice (Fig. 3A) displayed tonic–clonic
SLEs which were negligibly affected by CBZ. The tonic SLEs
from the nonHS-MTLE slice (Fig. 3B) became smaller, the
large amplitude events were reduced in number but addi-
tional small amplitude events occurred. In striking contrast,
Fig. 2 Types of epileptiform activity in the dentate gyrus of slices
from sclerotic and non-sclerotic hippocampal specimens of
MTLE-patients: changes of activity parameters by 50 mM CBZ.
(A) Microphotographs of 30 mm thick sections stained with cresyl
violet (calibration bar = 5 mm) from specimens with and without
hippocampal sclerosis (HS; nonHS, respectively). (B) Types of
epileptiform activity: tonic-clonic SLE, ictal spiking, inter-ictal
spiking, and tonic SLE. Calibration bars for amplitude and time also
apply to the other traces; the small box left from each trace is the
marker of the type used in C. (C) Summary graph showing the
mean percentage of the reference value remaining after 20 min
perfusion with 50 mM CBZ-containing high K-ACSF (y-axis) for
each parameter (category-axis) and event type (see type markers
in B). Columns and error bars represent mean 6 SEM for the
different types of events. Note, that there are no significant
differences of CBZ effects between the event types.
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Fig. 3 Effects of CBZ (50 mM, 20 min) on slices of different patient groups: MTLE-HS, MTLE-nonHS, and tumour-nonHS.
(A) Tonic-clonic SLEs in an MTLE-HS-slice (A1) before perfusion with CBZ-high K-ACSF (control), (A2) at the end of the perfusion with
CBZ-high K-ACSF and (A3) 20 min after removal of CBZ (wash). (B) Tonic SLEs in an MTLE-nonHS-slice (B1–3). (C) Tonic
SLEs in a slice from the tumour-nonHS group (C1–3). Note that CBZ suppressed the activity only in the slice from the tumour-nonHS
group. (D) Summary graph displaying the mean percentage of the reference values remaining after perfusion with CBZ-high K-ACSF for each
parameter: ev/min = event rate; sfp = amplitude of slow field potential; peak = peak amplitude; duration = event duration;
frequency = intra-event frequency of potential fluctuations (>0.3 mV, time interval >3 ms); Pb, high frequency power (fi = 78–293).
Columns and error bars represent mean 6 SEM for slices of the MTLE-HS group (n = 34, white), the MTLE-nonHS group (n = 15, grey) and
the tumour-nonHS group (n = 11, black), including the one sclerotic slice of a CBZ-sensitive patient (sample traces in Fig. 4).
(E) CBZ-remaining averaged activity (mean 6 SEM of averaged normalized parameter values per slice given in percent) in each group.
(F) Proportion of slices maintaining the averaged activity at a level of 0–20, 21–70 or >70% in the three groups. After administration of
CBZ, epileptiform activity persisted in both MTLE groups, independent of hippocampal pathology, but became suppressed in the
tumour-group. Asterisks denote significant statistical differences (P < 0.05).
Table 1 Reference values of activity parameters for different epileptiform events in the dentate gyrus of MTLE-slices
Event parameter (unit) Tonic–clonic SLE
(mean 6 SEM)
Ictal spiking
(mean 6 SEM)
Inter-ictal spiking
(mean 6 SEM)
Tonic SLE
(mean 6 SEM)
n 17 10 11 8
Event rate (events/min) 1.5 6 0.24 61.0 6 4.47 20.0 6 2.91 1.0 6 0.15
sfp-amplitude (mV) 1.7 6 0.38 0.9 6 0.18 0.8 6 0.14 3.8 6 1.10
Peak amplitude (mV) 3.2 6 0.58 1.2 6 0.17 1.4 6 0.26 5.3 6 1.55
Duration (s) 24.7 6 4.77 0.2 6 0.04 1.5 6 0.52 21.8 6 7.66
Frequency (Hz) 6.9 6 1.37 5.1 6 4.06 6.6 6 5.04 7.2 6 4.58
Power (80–300 Hz) (103 mV2) 2.6 6 1.11 0.5 6 0.16 1.1 6 0.55 1.5 6 0.62
In order to consider the time course of epileptiform activity in absence of drug application (see Fig. 1B) these reference values have
been calculated as [(control value + wash value)/2].
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the tonic events in the nonHS-tumour slice (Fig. 3C)
completely disappeared already after 15 min perfusion with
CBZ-high K-ACSF and reappeared after removal of CBZ
within 40 min. This was also true in the sclerotic slice of
a CBZ-sensitive patient belonging to the tumour-group
(Fig. 4).
Results for all parameters and slice-groups are summar-
ized in Fig. 3D. With CBZ applied for 20 min, the mean
values for all parameters remained at 81–99% of the corre-
sponding reference values in slices of the HS-MTLE group
and in the order of 84–91% in slices of the nonHS-MTLE
group. In contrast, slices of the tumour-group were highly
sensitive to CBZ. The remaining percentage of activity
parameters after CBZ application was in the order of 6–17%
except for the power of the 78–293 Hz band (35%). One-
way analysis of variance revealed significant differences
between groups for all parameters. Additionally, the post hoc
tests showed that the remaining activity in both MTLE
groups was significantly different from that of the Tumour-
group while the HS- and nonHS-group of MTLE-patients
did not significantly differ from each other.
CBZ-induced changes in each of the six activity
parameters were highly correlated to each other (Pearson
correlation coefficients between 0.59 and 0.94, n = 60, all
with P < 0.001) and there was no significant difference
between them (n = 57, P = 0.38, Friedman test). Therefore,
we averaged the normalized parameter values for each
slice and classified activities remaining with CBZ at 0–20,
21–70 and >70% as suppressed, reduced and resistant,
respectively. The mean level of the remaining activity was
89 6 4.6% in the HS-MTLE-group, 87 6 9.6% in the
nonHS-MTLE-group, and with 14 6 6.0% significantly
lower in the tumour-group (Fig. 3E). Additionally, we have
to note that the activity persisted in 94% of the HS-MTLE
slices and in 87% of the nonHS-MTLE slices, but only in
9.1% of slices in the tumour-group (Fig. 3F, P < 0.001;
x2-test). In the remaining slices of each group, the activity
was found to be suppressed.
Prolongation of CBZ application has
insignificant effects on epileptiform activity
Although slices of the tumour-group responded to CBZ
within <20 min, we tested whether epileptiform activity
in MTLE-slices required a prolonged equilibration time to
get more affected by CBZ (Fig. 5). We tested 18 slices of
12 MTLE-patients for the effect of 40 min treatment with
50 mM CBZ. The sample traces of a HS- and a nonHS-slice
depicted in Fig. 5A and B show that the activity is ongoing
after 40 min perfusion with CBZ-high K-ACSF albeit the
sfp-amplitude was more reduced than after 20 min. We also
tested whether the ability of slices to develop epileptiform
activity could be changed by preconditioning the slices
with 50 mM CBZ-containing normal ACSF (Fig. 6). In this
set of experiments the slices were pre-equilibrated with
CBZ-ACSF for 20 min before changing the perfusion to
CBZ-high K-ACSF (n = 6, e.g. Fig. 6, upper traces) and
compared the occurring epileptiform activity to a second
trial of activity induced by high K-ACSF after intermittent
washout of CBZ and high K-ACSF for 60–90 min (e.g. Fig. 6,
lower traces). We recognized (i) that epileptiform activity
occurred despite pre-equilibration with CBZ, and (ii) that
the characteristics of this activity did not significantly differ
from activity in the absence of CBZ.
In 16 out of 18 slices (88.9%, Fig. 5C) the activity
persisted at a mean level of 92.9 6 2.36% in comparison
to 96.5 6 3.25% after 20 min (Fig. 5D, P = 0.23, n = 16,
Wilcoxon test). In such ‘resistant’ slices (91.7% of pati-
ents) there was no significant decline in any of the para-
meters analysed (Fig. 5E). In the remaining two slices
the activity became suppressed and reduced (up to 30%),
respectively.
Fig. 4 Sample traces of ictal spiking recorded from a slice of a
CBZ-sensitive patient presenting with tumour and HS. (A) Ictal
spiking after 20 min perfusion with high K-ACSF (control).
(B) Inter-ictal spiking after 10 min perfusion with CBZ-high
K-ACSF. (C) Complete suppression of epileptiform activity after
20 min perfusion with CBZ-high K-ACSF. (D) Recovery of ictal
spiking, 20 min after removal of CBZ from the epileptogenic buffer.
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Prolongation of CBZ application with
increased CBZ-concentration significantly
reduces amplitudes and high frequency
power but does not suppress
epileptiform activity
Next we investigated whether suppression of epileptiform
activity requires a higher dose of CBZ. We tested 10 slices
of six MTLE-patients for the efficacy of 100 mM CBZ
during prolongation of the anticonvulsant treatment (Fig. 7).
Indeed, the sample traces for two slices (Fig. 7A and B)
illustrate that with 100 mM CBZ the slow field potential
amplitude became more reduced than with 50 mM CBZ.
The epileptiform activity disappeared in 20% of the slices,
became reduced in 10%, and persisted in 70% (83% of
patients) (Fig. 7C) albeit at a lower level of 88 6 3.70%
compared with 103.9 6 4.95% after 20 min perfusion with
50 mM CBZ (Fig. 7D, P = 0.018; n = 7; Wilcoxon test).
Different from the effect of prolonged treatment with
50 mM CBZ, the amplitudes and power of the high fre-
quency band remaining with 100 mM CBZ were significantly
lower, even in slices with persistent activity (Fig. 7E, n = 7,
P = 0.018, 0.018, 0.028, respectively; Wilcoxon test).
MTLE- and tumour-patients are clinically
and neuropathologically different
The two patient groups displayed different clinical data
(Table 2). In comparison to the tumour-group, the MTLE-
group was characterized by long duration epilepsy and drug
resistance including resistance to CBZ/oxcarbazepine. At
surgery, the MTLE-patients were more often treated with
Fig. 5 Effects of prolonged administration of CBZ (50 mM, 40 min) on slices of the MTLE-group. (A) Sample traces of tonic–clonic
SLEs in a sclerotic slice (HS): (A1) after 20 min perfusion with high K-ACSF (control), (A2) after 20 min perfusion with CBZ-high K-ACSF,
(A3) after 40 min perfusion with CBZ-high K-ACSF, and (A4) after another 40 min perfusion with high K-ACSF (wash). (B) Sample traces
of tonic SLEs in a slice from a nonHS specimen at corresponding periods (B1–4). Calibration bars for amplitudes at right of each
trace display 5 mV; the calibration bar for time is given below traces A4 and B4. Both slices showed a reduction of the amplitude of slow
field potential shifts by CBZ but no suppression of activity. (C) Summary graph displaying the proportion of slices with CBZ-remaining
averaged activity (rem. av. activity) at levels >70, 21–70 or 0–20% categorized as resistant, reduced or suppressed, after 40 min
perfusion with CBZ-high K-ACSF. (D) Level of CBZ-remaining averaged activity in the sub-group of resistant slices (>70%, n = 16) after
20 min (grey) and after 40 min perfusion with CBZ-high K-ACSF (black). Columns and error bars represent mean 6 SEM of averaged
normalized activity parameters per slice, given in percent. (E) Percentage of the reference value remaining after 20 and 40 min
perfusion with CBZ-high K-ACSF (grey and black, respectively) for each parameter (denoted as in Fig. 3D). Columns and error bars
represent mean 6 SEM for the resistant sub-group. Note that there are no significant differences of any activity parameter between the
periods of 20 and 40 min perfusion with CBZ-KACSF in this group.
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two AEDs (P = 0.017, x2-test). The mean plasma con-
centration of AEDs was predominantly within the ther-
apeutic range [in mg/ml: CBZ 10.2 6 0.46 (range 7.9–12.2, n
= 10), the primary metabolite of oxcarbazepine, 10-OHCBZ,
24.6 6 1.82 (range 13–32.5, n = 9), lamotrigine 5.3 6 1.15
(range 2.4–10, n = 6), levetiracetam 17.9 (n = 1); on average
70 6 3% of the maximum concentration of each substance
found in the whole data sample]. Relatively more patients in
the MTLE-group had low frequency seizure rates and a
higher trend to secondary generalization. Additionally, the
MTLE-patients showed a higher incidence of hippocampal
sclerosis (HS: Wyler grades 3 and 4). In contrast, the patients
in the tumour-group (mainly extra-hippocampal dysem-
bryoblastic neuroepithelial tumour, ganglioglioma WHO
grade 1 and astrocytomas WHO grades 1 or 2) experienced
only short periods of epilepsy and drug treatment. One
patient did never display a seizure and did not take in any
AED, a 2-year-old boy got 360 mg valproate per day, and the
remaining four patients obtained CBZ or oxcarbazepine.
The corresponding plasma levels were also in or just below
the therapeutic level [in mg/ml: CBZ 11.6 6 0.91 (n = 3), 10-
OHCBZ 13.02 (n = 1), and valproate 72 (n = 1); on average
69 6 9.6% of the maximum concentration of each substance
in the data sample]. One patient became seizure-free
by treatment with 1200 mg CBZ per day (plasma level
12.5 mg/ml). All six patients except the last one
presented with low degrees of cell loss (nonHS: Wyler
grades 1 and 2).
Outcome of surgery has been determined for 33 patients
(Engel, 1987): 54.5% were seizure free (Engel 1A), 15.2%
were free of disabling seizures (Engel 1B–D), 15.2% had
rare seizures (Engel 2), 12.1% were worthwhile improved
(Engel 3) and 3.0% had no improvement (Engel 4). With
respect to outcome there was no difference between the
MTLE- and the tumour-group (P = 0.983, x2-test).
In vitro efficacy of CBZ coincides with cause
of epilepsy, history of the patient’s CBZ-
resistance, age at operation and duration
of epilepsy
In order to analyse whether sensitivity to CBZ in resected
hippocampal tissue is statistically related to clinical data,
the normalized parameter values remaining after treatment
with CBZ in each slice were averaged per patient, and
subsequently averaged over all parameters. The resulting
percentages of CBZ-remaining averaged activity in the data
sample of patients (histogram Fig. 8A) were categorized as
suppressed, reduced or resistant according to levels of 0–20,
21–70 or >70%, respectively, as already done with the slices
(histogram Fig. 8B). Accordingly, the patients showing
CBZ-remaining activities at corresponding levels have been
classified as showing ‘high’, ‘partial’ and ‘low’ efficacy of
CBZ, respectively.
Resistance of activity was evident in tissue of 23 patients
(low efficacy-group, 68% of patients in the whole sample).
Suppression of activity was observed in tissue of seven
patients (high efficacy-group, 20%). An apparent reduction
of activity was seen in tissue of four patients (partial efficacy
group, 12%). In three out of the last four patients, the
‘reduction’ resulted from averaging data of both one slice
displaying suppression of activity by CBZ and another one
displaying resistance, possibly indicating that drug resistance
may be focally expressed. One example is illustrated in
Fig. 8C1 and C2. Together, about one-third of patients
presented with high or partial efficacy of CBZ in the resected
tissue. As patients showing high efficacy of CBZ in the
resected hippocampus were mainly tumour-patients (71.4%)
and patients showing low efficacy of CBZ were MTLE-
patients (100%), the two sub-groups differ not only in the
proportional distribution of tumour- and MTLE-patients
(x2 = 14.907, P < 0.001) but also with respect to some of
their different clinical data, already documented in Table 2
(Fig. 9).
High efficacy of CBZ in resected hippocampal tissue
coincided with clinically unproven drug resistance, CBZ-
sensitivity or no treatment. By contrast, low efficacy of CBZ
coincided with clinically proven drug resistance, including
CBZ-resistance (Fig. 9A; P = 0.001, x2-test). Besides, high
efficacy of CBZ in the resected tissue was seen in patients of
younger age (24.96 4.71 versus 40.76 2.54 years, P = 0.006),
Fig. 6 SLEs occurred in slices preconditioned with CBZ.
(A) Sample trace of SLEs recorded in a slice from a sclerotic
specimen (Wyler 3). The slice has been pre-equilibrated with
50 mM CBZ in normal ACSF for 20 min and then treated with
50 mM CBZ-containing high K-ACSF (10 mM K+) for
another 20 min. (B) Same slice at the end of a second trial
of 20 min perfusion with high K-ACSF, after intermittent washout
of CBZ-high K-ACSF for 90 min.
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shorter duration of epilepsy (7.5 6 4.47 versus 22.9 6 2.90
years, P = 0.005), and shorter treatment with CBZ (1.5 6
0.71 versus 5.9 6 0.80 years, P = 0.003) (Fig. 9B). There was
no difference between the two sub-groups with respect to
age at onset of epilepsy, seizure type and seizure frequency,
drug treatment at operation, and plasma concentrations of
the AEDs (as far as normalized with respect to the maximum
level for each drug detected within the sample of data). The
third sub-group displaying partial efficacy of CBZ did not
differ from each of the two other sub-groups. The
proportional distribution of the three sub-groups of patients
showing different efficacy of CBZ in the resected tissue only
insignificantly changed with equilibration time of CBZ or
even with higher concentration of CBZ during prolonged
application (Fig. 9C).
Sensitivity to CBZ and tissue excitability
The [K+]o at which stimulus-associated epileptiform dis-
charges appeared [threshold [K+]o] might reflect the degree
of hyperexcitability in the epileptic tissue. This threshold
[K+]o was higher for patients whose slices responded to CBZ
with suppression of activity than for patients who did not
[9.0 6 0.52 (range 6.85–11.48) versus 7.2 6 0.28 (range
4.35–9.59) mM (n = 30, P = 0.003, Mann–Whitney-test)].
Moreover, there was a significant inverse correlation
Fig. 7 Effects of CBZ (100 mM) during prolongation of treatment for another 20 min in slices of the MTLE-group. (A) Sample traces of
tonic-clonic SLEs in a slice from a sclerotic specimen (HS): (A1) after 20 min perfusion with high K-ACSF (control), (A2) after 20 min
perfusion with CBZ-high K-ACSF (50 mM), (A3) after additional 20 min perfusion with CBZ-high K-ACSF (100 mM), and (A4) after another
60 min perfusion with high K-ACSF (wash). (B) Sample traces of tonic SLEs in a slice from a non-sclerotic specimen (nonHS) at
corresponding periods (B1–4). Calibration bars for amplitudes at right of the top traces also apply to the other traces from the
same slice; the calibration bar for time is given below the traces A4 and B4. Both slices showed a reduction of the amplitude of slow field
potential shifts under CBZ but no suppression of activity. (C) Summary graph displaying the proportion of slices with CBZ-remaining
averaged activity (remaining averaged activity) at levels >70, 21–70 and 0–20% (categorized as resistant, reduced and suppressed,
respectively) after additional 20 min perfusion with CBZ-high K-ACSF (100 mM). (D) Level of CBZ-remaining averaged activity
(mean 6 SEM of averaged normalized activity parameters per slice, given in percent) in the sub-group of resistant slices (n = 7) after
20 min perfusion with CBZ-high K-ACSF (50 mM, grey) and after additional 20 min perfusion with CBZ-high K-ACSF (100 mM; black).
(E) Percentage of the reference value remaining after similar periods of treatment (grey and black, respectively) for each parameter
(denoted as in Fig. 3D). Columns represent mean 6 SEM for the resistant sub-group. Note a significant reduction of the averaged
activity in D and of amplitudes as well as power of the 78–293 Hz frequency band after the treatment with 100 mM CBZ,
even in the resistant slices (E). Asterisks denote significant statistical differences (P < 0.05).
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between the CBZ-remaining averaged activity and the thres-
hold [K+]o-values (Spearman rho: r = 0.44, P = 0.010,
n = 34; Fig. 9D; pooled sample of MTLE- and tumour-
patients). Notably, when MTLE-patients were tested sepa-
rately, the mean threshold [K+]o-values of patients showing
high or low efficacy of CBZ in the slice did not significantly
differ and the spread diagram of the remaining averaged
activities and the threshold [K+]o-values (Fig. 9D, empty
circles) revealed only a weak and insignificant correlation
of the two parameters (Spearman rho r = 0.29, P = 0.149,
n = 27). This may indicate that the correlation found in
the whole population reflects rather a different distribution
of both hyperexcitability and drug resistance between
patients operated on MTLE and on extra-hippocampal
tumours than a dependence of CBZ-effects on excitability of
the tissue.
Discussion
Ourmain results show that epileptiform activity in the dentate
gyrus of drug-resistantMTLE-patients is predominantly CBZ-
resistant, irrespective of the presence of hippocampal sclerosis
and independent of the equilibration time of the drug. In
contrast, epileptiform activity was CBZ-sensitive in slices of
patients with extra-hippocampal tumours and with a short
history of epilepsy. As CBZ, directly applied into hippocampal
slices of resected tissue, has not to cross the BBB in order to
reach cellular targets, our results indicate that the parenchyma
of the dentate gyrus containsmechanisms ofCBZ-resistance in
most of the MTLE-patients. The results also suggest that drug
transporters at the BBB are not determinants of dentate
CBZ-resistance butmight be responsible for drug resistance in
twoMTLE-patients (7%) whose slices were found to be highly
sensitive to the drug.
Table 2 Summary of selected patient data
Variable categories MTLE (n = 28) Tumour (n = 6) Total (n = 34) P
Duration of epilepsy in years [mean (6SEM)] 23.2 (2.43) 1.1 (0.29) 19.3 (2.48) 0.001
Effect of CBZ or OXC
No treatment (%) 0.0 33.3 5.9 0.001
Proven suppression (%) 0.0 16.7 2.9
Proven resistant (%) 100.0 0.0 82.4
Not proven (%) 0.0 50.0 8.8
Duration of treatment in years [mean (6SEM)] 5.7 (0.70) 0.5 (0.23) 4.8 (0.67) 0.001
AEDs at surgery
No drug (%) 0 16.7 2.9 0.072
(a) OXC/CBZ (%) 39.3 50.0 41.2
(b) LEV/LTG, (%) 14.3 33.3 17.6
(c) (a) + LEV/LTG/TPX/GBT (%) 17.9 0.0 14.7
(d) LTG + LEV/VPA/PB/DZ (%) 28.6 0.0 23.5
Gender
F (%) 57.1 16.7 50.0 0.072
M (%) 42.9 83.3 50.0
Age at surgery in years [mean (6SEM)] 39.9 (2.13) 22.0 (4.73) 36.7 (2.25) 0.001
Age at onset in years [mean (6SEM)] 16.3 (2.20) 21.0 (4.67) 17.1 (1.98) 0.373
Approximated seizure frequencies
No seizure (%) 0 33.3 5.9 0.009
<5/month (%) 35.7 0.0 29.4
5–15/month (%) 53.6 50.0 52.9
>15/month (%) 10.7 16.7 11.8
Generalization
No (%) 28.6 83.3 38.2 0.039
<1 SGS/year (%) 28.6 0.0 23.5
>1 SGS/year (%) 42.9 16.7 38.2
Hippocampal pathology
NonHS (%) 32.1 83.3 41.2 0.021
HS (%) 67.9 16.7 58.8
Numbers in the table represent mean values (SEM) or proportion (%) of patients within two groups. One group has been operated on
MTLE characterized by clear resistance to treatment with CBZ or OXC (oxcarbazepine). The other one consisted of patients operated
on tumours. These patients were not—or only shortly—treated with CBZ/OXC.
(a) and (b): one of the drugs is given; (c) and (d): the first drug is given in combination with one of the other drugs.
n = number of patients in the group. P = error probability of inter group differences (one-way variance analysis, x2-test);
TLE = temporal lobe epilepsy; LEV = levetiracetam; LTG = lamotrigine; VPA = valproic acid; TPX = topiramate; DZ = diazepam;
PB = phenobarbital; SGS = secondary generalized seizure; nonHS = no hippocampal sclerosis (Wyler grades 0–2); HS = hippocampal
sclerosis (Wyler grades 3–4).
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Is the model of epilepsy used to test drug
resistance in the slice CBZ-sensitive?
The first question is whether the high potassium-induced
epileptiform activity might be per se pharmaco-resistant or
in certain forms of activity less sensitive. Inter-ictal activity
in areas CA3/CA2 (Rutecki et al., 1985; Korn et al., 1987;
Colom and Saggau, 1994) and seizure-like events in area
CA1 (Traynelis and Dingledine, 1988; Jensen and Yaari,
1997), induced by elevation of [K+]o in normal rat slices,
were blocked by the glutamate receptor antagonist 6-cyano-
7-nitroquinoxaline-2,3-dione (CNQX) (Leschinger et al.,
1993) and by AEDs, in particular CBZ (Leschinger et al.,
1993; Arias and Bowlby, 2005). We already showed that
stimulation-high K+-induced self-sustaining epileptiform
activity occurring in the dentate gyrus from human epileptic
hippocampal tissue was suppressed by CNQX and by
lowering extracellular calcium concentration (Gabriel et al.,
2004). Now, we report that this synaptically mediated
epileptiform activity was blocked by CBZ in 91% of slices
from hippocampal tissue of patients with extra-hippocampal
tumours. Additionally, in slices of MTLE-patients, each type
of activity was found to be similarly affected by CBZ. Thus,
data obtained from both the rat and human hippocampus
provide arguments against the assumption that drug resis-
tance is a property of high K+-induced epileptiform activity.
Is CBZ actually a substrate of human
drug transporters?
The fact that the epileptic dentate gyrus in slices of drug-
resistant patients is predominantly CBZ-resistant renews
the question, whether CBZ is a substrate of drug efflux
pumps (Potschka et al., 2001, 2003). Other studies revealed
that CBZ at therapeutically relevant concentrations did not
interact with drug efflux pumps or inhibit those (Owen et al.,
2001; Maines et al., 2005; Weiss et al., 2003). In MTLE-
patients, the hippocampus to plasma concentration ratio of
the primary active oxcarbazepine-metabolite 10-OHCBZ
was found to be inversely correlated to the MDR1-mRNA
Fig. 8 Analysis of in vitro efficacy of CBZ in patients and slices reveals opposite effects of CBZ in different slices of one specimen. In order to
categorize the patient with respect to in vitro efficacy of CBZ, all normalized CBZ-remaining parameter values in single slices were
averaged per patient and averaged over all parameters. (A) Bimodal histogram of CBZ-remaining averaged activities per patient.
(B) Bimodal histogram of CBZ-remaining averaged activities per slice. (C1 and C2) Effects of CBZ in two slices from one sclerotic
hippocampal specimen, showing suppression of activity by CBZ in slice C1 and resistance of activity in slice C2. Comparison of the two
histograms, A and B, reveals values of three patients (marked by arrows) resulting from such partial efficacy of CBZ in the dentate gyrus of
resected tissue.
Carbamazepine in human epileptic tissue Brain (2006), 129, 3290–3306 3301
 by guest on June 2, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
levels (Marchi et al., 2005). This strengthens the assump-
tion that P-glycoprotein (Pgp) which is up-regulated by
MDR1-mRNA impairs access of oxcarbazepine to the
focal epileptic tissue. Whether CBZ like oxcarbazepine
would have reduced brain access in drug-resistant patients
remains to be investigated. Therefore, suggesting BBB-
located resistance mechanisms when dentate epileptiform
activity in slices is suppressed by directly applied CBZ is
still not conclusive.
The dentate gyrus of MTLE-patients
contains CBZ-resistance mechanisms
irrespective of the hippocampal pathology
In the majority of slices prepared from resected hippo-
campal tissue of MTLE-patients, the granule cell popula-
tions did not adequately respond to therapeutically relevant
concentrations of CBZ, despite free access of the drug to the
cellular targets. Therefore we propose that drug resistance
mechanisms exist in the parenchyma and might be
determined by several factors.
The results from whole cell patch clamp recordings in
isolated dentate granule cells of MTLE-patients and from
chronic epileptic animals showed that CBZ did not slow
the recovery from inactivation of voltage-gated sodium
channels and did not augment the use- and frequency-
dependent block of these channels (Reckziegel et al., 1999;
Remy et al., 2003a). Thus, we assume that reduced CBZ-
sensitivity of voltage-gated sodium channels is one factor
causing CBZ-resistance of epileptiform activity. However,
epilepsy-related changes in the properties of sodium
channels, which were recently reviewed (Remy and Beck,
2006), differ depending on the cell-type examined
(Vreugdenhil et al., 1998 versus Remy et al., 2003a), on
the AED studied (Remy et al., 2003a,b), and on the epilepsy
model investigated (Vreugdenhil and Wadman, 1999 versus
Fig. 9 Relationship between in vitro efficacy of CBZ and clinical data, in vitro treatment conditions, and excitability of the tissue as revealed by
the threshold potassium concentration at appearance of stimulus-associated epileptiform discharges. Efficacy of CBZ was categorized
as low, partial or high if the CBZ-remaining averaged activity per patient remains at >70, 21–70 or 0–20%, respectively (see histogram
Fig. 8A). (A) Proportional distribution of different clinical categories for CBZ-treatment/history (indicated right from the graph) in patient
groups subdivided according to the different levels of CBZ-remaining averaged activity in the resected tissue, given on the category-axis.
(B) Age, duration of epilepsy and duration of CBZ-treatment (y-axis) in the same three sub-groups, marked as shown in the right upper
corner of the graph. Columns representing mean 6 SEM are grouped with respect to the three clinical parameters indicated
below the category-axis. Numbers of patients in the sub-groups are given left below the category-axis for age. (C) Proportional distribution
of the sub-groups within groups of specimens (MTLE-patients) tested for different treatment conditions, given below the category-axis.
(D) Spread diagram showing the relation between CBZ-remaining averaged activity in the tissue (y-axis) and threshold [K+]o at
occurrence of stimulus-associated epileptiform discharges (x-axis). Linear regression lines are given for the pooled sample of patients and for
MTLE-patients only. Asterisks mark significant differences (P < 0.05) between patient groups.
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Remy et al., 2003a). Therefore, our conclusions might
be restricted to the dentate gyrus, to the drug CBZ, and to
the high K+-model of epilepsy.
Another factor implicated in parenchymal CBZ-resistance
might be drug efflux by transporter proteins expressed
in relatively healthy neurons (MRP5) and astrocytes (MRP4,
MRP5), for example in perilesional cortex (Nies et al., 2004),
or overexpressed in neurons and/or astrocytes (Pgp, MRP1,
MRP5) which reside in different epileptogenic pathologies
(Sisodiya et al., 2002; Aronica et al., 2003a, 2004; Lazarowski
et al., 2004; Vogelgesang et al., 2004). As already discussed, it
is presently not clear whether and which efflux pumps
transport CBZ. Nevertheless, if CBZ-resistance was signifi-
cantly supported by parenchymal drug transporters ‘exclu-
sively expressed in sclerotic hippocampi’ (Aronica et al.,
2004) sclerotic tissue would be less sensitive to CBZ than
non-sclerotic tissue. However, similar to effects of valproate
on sodium currents in area CA1 (Vreugdenhil et al., 1998),
the effects of CBZ on epileptiform activity in the dentate
gyrus did not differ between sclerotic and non-sclerotic
tissue, suggesting that dentate CBZ-resistance resembles
CBZ-resistance of MTLE-patients, irrespective of the
presence of hippocampal sclerosis. Additionally, it should
be taken into account that CBZ, phenytoin and
lamotrigine block sodium channels only when externally
applied (Kuo, 1998). As the transporter pumps the drug out
of the cell towards the extracellular side of the membrane, a
contribution of drug transporters to failure of cellular CBZ-
responses is not very likely, but remains to be experimentally
tested.
The third factor hypothetically involved in drug resistance
is synaptic reorganization of excitatory and inhibitory
neuronal circuits evident as mossy fibre sprouting, preserva-
tion of GABAergic inhibition, sprouting of perisomatic
inhibitory fibres and loss or alteration of specific inter-
neurons (Babb et al., 1989; de Lanerolle et al., 1989; Sutula
et al., 1989, Houser et al., 1990; Lehmann et al., 2000;
Magloczky et al. 2000; Wittner et al., 2001). In human
MTLE, these changes are most pronounced in sclerotic
tissue and partially present in non-sclerotic tissue. This
suggests different degrees of hyper-excitation, hyper-
inhibition, synchronization, impairment of dendritic granule
cell inhibition, reduction of interneuron-selective inhibition
and contribution to failure of GABAergic AEDs, when
granule cells become activated (Magloczky and Freund
2005). With focus on the present study, reorganization
might support induction of epileptiform activity by mossy
fibre activation (hilar stimulation) and neuronal depolariza-
tion [elevation of [K+]o]. The different levels of reorganiza-
tion might be responsible for the expression of different
types of epileptiform activity in sclerotic and non-sclerotic
tissue (Gabriel et al., 2004). However, the result that effects
of CBZ on epileptiform activity were similar with respect
to the type of activity, the degree of sclerosis or the degree
of excitability (K+-threshold) did not provide any hint on
relations between CBZ-resistance and different levels of
synaptic reorganization. Since reorganization of inhibitory
circuits has not been investigated in the tissue tested for
the efficacy of CBZ, the question whether it might be a
factor of CBZ-resistance remains open.
The dentate gyrus of patients with
extra-hippocampal tumours is
CBZ-sensitive
We observed high efficacy of CBZ in the dentate gyrus
of hippocampal slices in the majority of patients with
primary extra-hippocampal tumours and only in a minority
of MTLE-patients.
With respect to the tumour-patients we should consider
that their CBZ-sensitivity in the dentate gyrus of the hippo-
campal slice has several clinical and experimental scenarios.
The group comprised (i) a patient without epilepsy, with-
out hippocampal pathology, and with the highest thres-
hold [K+]o (11.5 mM at occurrence of stimulus-induced
discharges), (ii) a drug-sensitive patient with HS and a lower
threshold [K+]o (6.85 mM), and (iii) four patients with a
short history of persistent seizures (not proven drug-
resistant), non-sclerotic hippocampus, and a threshold
[K+]o >8 mM. In combination, the high efficacy of CBZ
and the high threshold [K+]o in hippocampal slices of
patients with primary extra-hippocampal tumours reflect
that the recordings were made in normal or mostly para-
lesional hippocampus showing a low degree of hyperexcit-
ability. Therefore, we assume that para-lesional hippocam-
pus resected after short duration of epilepsy and treatment is
still drug-sensitive. This might be supported by the finding
of partial efficacy after 1.8 years of persistent seizures in the
one patient whose tumour partially infiltrated the hippo-
campus.
CBZ-resistance is rarely located at the
hippocampal BBB
With focus on clinically proven CBZ-resistant MTLE-
patients it is worth mentioning that high efficacy of CBZ
was observed in only two specimens (one HS, one nonHS).
As the serum concentration of drugs in the two patients
was sufficiently high, the resistance mechanisms might be
located at the BBB. At the BBB, drug transporters like
Pgp and multidrug-resistance associated proteins (MRP1,
MRP2, MRP4, MRP5) are present or overexpressed in
capillary endothelial cells or in astrocytes around the lesional
microvasculature (Golden and Pardridge, 2000; Sisodiya
et al., 2002, 2006; Aronica et al., 2004; Nies et al., 2004;
Kubota et al., 2006). Whether overexpression of Pgp and
MRP2 in microvessels of the hippocampus is actually
restricted to sclerotic tissue (Aronica et al. 2004) or may
be also found in non-sclerotic cases, as indicated by a
reduced brain-to-plasma drug concentration ratio accom-
panied by increased expression of MDR1-mRNA in two out
of four non-sclerotic specimens in the work of Marchi and
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colleagues (Marchi et al., 2005), is presently not clear.
Alternatively, it is conceivable that the dentate gyrus found
to be highly or partially sensitive to CBZ in five MTLE-
patients was not or only focally involved in drug resistance
and seizure activity. This assumption is supported by the
relatively high threshold [K+]o in the slices of these patients.
Outcome and further tasks
Our findings reveal that the dentate gyrus of hippocampal
tissue obtained from MTLE-patients with a long history
of epilepsy is CBZ-resistant. This resistance is based on
mechanisms located in the parenchyma, independent of
hippocampal pathology. The CBZ-resistance in the slice
resembles CBZ-resistance of the patient, likely to be
explained by reduced target-sensitivity. Accordingly, our
data supporting drug resistance by increased drug efflux at
the BBB were disappointingly rare and not conclusive. The
findings suggest that at least the dentate gyrus of MTLE-
patients remains drug-resistant when drug transporters at
the BBB could be blocked by new medicaments. Two things
remain to be done. (i) To rule out that CBZ-resistance in the
dentate gyrus is a regional particularity and possibly
irrelevant for the patient’s drug resistance, the efficacy of
several AEDs needs to be studied not only in the dentate
gyrus but also in other regions involved in seizure activity
and drug resistance (e.g. the temporal cortex). (ii) The
function of drug transporters ectopically expressed in
neurons and astrocytes of epileptic tissue (Marchi et al.,
2004) has not been determined in relation to the cellular
drug response. In order to estimate their contribution to
parenchymal drug resistance the efficacy of AEDs should
be tested in presence of drug transporter inhibitors.
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